1st Sep 2008 10:13
1st September 2008
AGI Therapeutics PLC
Notification of Results
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, will be announcing its interim results for the six months ended 30 June 2008 on Tuesday, 9 September 2008.
An analyst briefing will be held at 09.30am UK time at the offices of Piper Jaffray, One South Place, London EC2M 2RB.
Contact Information:
|
AGI Therapeutics plc. |
Tel: +353 1 449 3254 |
|
David Kelly, Chief Financial Officer |
|
|
Financial Dynamics - UK |
Tel: +44 (0) 20 7269 7182 |
|
Jonathan Birt/Lara Mott |
|
|
Financial Dynamics - Ireland |
Tel: +353 1 663 3607 |
|
Aisling Garvey |
|
|
Piper Jaffray Limited Neil Mackison Will Carnwath |
Tel: +44 (0) 20 3142 8700 |
|
Davy John Frain |
Tel: +353 (1) 614 8761 |
Notes to Editors:
About AGI Therapeutics plc
AGI is a speciality pharmaceutical company which is focused on the development and commercialisation of differentiated drug products for gastro-intestinal (GI) diseases and disorders. AGI's common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.
The Company has a portfolio of product candidates derived from its Known Molecular Entity (KME) approach to drug re-profiling and development. The Company's lead product candidate, Rezular™, is an orally administered triple-action intestinal regulator, a first-in-class mechanism for the treatment of diarrhoea predominant Irritable Bowel Syndrome (IBS-D).
KME is a re-profiling methodology used by the Company to identify existing therapeutic drugs which typically have been marketed for a number of years, have established safety profiles and can be developed for new clinical indications or with improved profiles in their existing clinical indications. In this way, the Company seeks to reduce the risk, time and cost of new product development as compared to the development of new chemical entities.
AGI is developing a range of product candidates to treat a variety of prevalent GI diseases and disorders, including irritable bowel syndrome (IBS), dyspeptic symptoms, gastroparesis, ulcerative colitis, gastro-esophageal reflux disease (GERD) and diarrhoea-related conditions such as chemotherapy-induced diarrhoea (CID). The Company is targeting areas of the GI therapeutic drug products market for its product candidates where there are currently unmet medical needs or where the effectiveness of existing drug therapies can be further improved.
The Company has five active clinical stage product candidates which are either isomers or new drug delivery formulations of existing approved drugs and which have established safety and tolerability profiles in their currently approved clinical indications.
For further information please see www.agitherapeutics.com.
Related Shares:
Potentially Ai